RAFA Stock UPDATES Rafarma Pharmaceuticals Inc. [Wy] (RAFA) 0.0800

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Rafarma Pharmaceuticals Inc. [Wy] (RAFA) 0.0800 $RAFA

Rafarma Pharmaceuticals (RAFA) Announces New President as Part of Pending Acquisition of Majority Interest
GlobeNewswire - Wed Jul 30, 1:40PM CDT
Rafarma Pharmaceuticals Inc. (Pink Sheets:RAFA) announces the appointment of Mr. Bruno Horn, a Swiss citizen, as the new President and Director of the Company, effective July 15, 2014. Mr. Horn is the founder of his own consultancy based in Switzerland, specializing in steel trading and the pharmaceutical industry. Mr. Horn started his career as a trader in raw materials and semi-finished products, as well as, OEM products for Olivetti. Mr. Horn served as head of back office for Olivetti Group's financial operations. Mr. Horn was in charge of international flat steel trade structure for Olsher Metals, a US based group, before joining the Lucchini Group with their flat products sector and organizing the sales structure for the US. Mr. Horn, also served as independent consultant for CMM, a US based company active in the field of securitizations. Most recently, Mr. Horn was director of finance for MMK Steel of Russia. Mr. Horn brings significant experience in finance and operational management particularly in Russia markets.

Restructuring offers Assurance of Rafarma Pharmaceuticals' Improved Financial Future
PR Newswire - Wed Apr 02, 10:00AM CDT
Rafarma Pharmaceuticals Inc. (OTC RAFA) is pleased to announce the complete restructuring of its existing EUR 90,000,000.00 loan with VNeshconombank (VEBank), Russia's premier development bank. Terms and conditions of the restructured loan include a 3-year deferment, or holiday, on all principal and interest payments thus greatly enhancing the financial stability of the company.

Rafarma Pharmaceuticals (OTC:RAFA) Announces Cooperative Agreement with the St. Petersburg Academy of Pharmaceutical Chemistry
PR Newswire - Wed Feb 05, 7:00AM CST
On February 3, 2014, ZAO Rafarma management met with senior faculty members of the St. Petersburg Academy of Pharmaceutical Chemistry to create a long-term cooperative agreement.

Governor's Initiative Paves Way For Pharmaceutical Joint Venture Between Rafarma Pharmaceuticals And St. Petersburg-Based Pharmsynthez
PR Newswire - Tue Jan 28, 10:02AM CST
Rafarma Pharmaceuticals (OTC:RAFA) and St. Petersburg-based Pharmsynthez have opened discussions for Joint Venture Production.

Rafarma Pharmaceuticals, Inc. (RAFA) announces plans for PCAOB-Registrant Audit and Streamlining of Corporate Structure to Upgrade Market Listing.
PR Newswire - Thu Sep 19, 8:15AM CDT
Rafarma Pharmaceuticals (OTC:RAFA), in an effort to upgrade its market listing has announced plans for a full audit and a streamlining of its corporate structure.

Rafarma Pharmaceuticals, Inc. (RAFA) Enters New Distribution Agreement with Amber Pharma Distribution Group
PR Newswire - Tue Sep 10, 8:05AM CDT
Rafarma Pharmaceuticals, Inc., OTC symbol "RAFA," announced it has entered into a new multi-year distribution contract with Amber Pharma Distribution Group, a boutique international business development firm. The principals of Amber Pharma have more than 75 years of combined international business development experience in a wide range of industry sectors including pharmaceuticals, finance, software, telecommunications and trade. It is intended that this new alliance with Rafarma will lead to over $100 million USD in new sales within the next 24 to 36 months.

Rafarma Pharmaceuticals, Inc. (RAFA) New Dialysis Research and Development Center to Join Rafarma in Making Terbuny Russia's New Biotech Hub
Marketwire - Fri Aug 02, 10:10AM CDT
The success of Rafarma Pharmaceuticals, Inc. (OTC: RAFA) in choosing Terbuny for its facility has attracted more biotech companies to the area. A new facility specifically devoted to dialysis research and product development has been announced.

Rafarma Pharmaceuticals, Inc. (RAFA) Announces Cooperative Effort With Christian Albrecht University in Kiel, Germany
Marketwire - Thu Jul 25, 8:40AM CDT
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) announces a cooperative research and development effort with Christian Albrecht University in Kiel on the following projects:

Rafarma Pharmaceuticals, Inc. (RAFA) Operational Subsidiary Introduces New Board of Directors
Marketwire - Wed Jul 17, 9:08AM CDT
The pharmaceutical plant operations of Rafarma Pharmaceuticals, Inc. (OTC: RAFA) are run by its operational subsidiary, "ZAO Rafarma." Day-to-day production activities, as well as operational and business expansion, are led by a well-qualified team of pharmaceutical and business professionals. A new Board of Directors for ZAO Rafarma was recently elected and includes the following industry veterans:

Rafarma Pharmaceuticals, Inc. (RAFA) Enters Into New Exclusive Production Contract With JSC F-Synthesis to Produce Anti-Cancer Drug Imatinib
Marketwire - Tue Jul 16, 12:48PM CDT
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) announces the signing of a new exclusive production agreement with JSC F-Synthesis for the production of the anti-cancer drug Imatinib.

Rafarma Pharmaceuticals, Inc. (RAFA) Enters Into New Production Contract for Para-Aminosalicylic Acid
Marketwire - Fri Jul 05, 9:28AM CDT
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) is pleased to announce that in June of this year the Company entered into a production agreement to manufacture Para-Aminosalicylic Acid (PAS) to be marketed and distributed by OOO "Advance Trading," which is one of the leading distributors of PAS in Russia.

Rafarma (RAFA) Enters $50,000,000 Ceftriaxone Market and Signs Long-Term National and Regional Distribution Contracts
GlobeNewswire - Thu Jun 06, 8:18AM CDT
Rafarma Pharmaceuticals, Inc. (the "Company" (Pink Sheets:RAFA) announces commencement of production of the antibiotic Ceftriaxone.

Rafarma Pharmaceuticals, Inc. (RAFA) Announces Engagement of QualityStocks Investor Relations Services
Marketwire - Wed Apr 10, 7:00AM CDT
Rafarma Pharmaceuticals, Inc. (PINKSHEETS: RAFA) announces today that they have agreed with QualityStocks to be featured in The Small Cap QualityStocks Daily Newsletter, QualityStocks Daily Blogs and Message Boards. QualityStocks, based in Scottsdale, Arizona, is a free service that collates data from hundreds of Small-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts.

Rafarma Pharmaceuticals Registers CEFTRIAXONE Under International Label
Marketwire - Mon Apr 08, 7:02AM CDT
Rafarma Pharmaceuticals, Inc. (PINKSHEETS: RAFA), a Russia-based multi-product pharmaceutical company producing generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products, today announces that ZAO "Rafarma" has registered (MHH) CEFTRIAXONE, a third-generation cephalosporin antibiotic, as a medication under international unpatented label.

Rafarma Pharmaceuticals, Inc. Receives General License for Pharmaceutical Products and has Started to Manufacture 3 New Products
PR Newswire - Mon Feb 04, 8:15AM CST
Rafarma Pharmaceuticals, Inc. (the "Company" OTC symbol (RAFA) announced that it has received the general license for pharmaceutical products and has started the manufacturing of 3 new products. The general license was one of the final steps required to open the new plant in Terbuniy. The Company is now in operation and is expected to rapidly increase to 100% capacity of the Terbiniy facility with the addition of government contracts provided by being 1 of 4 National Strategic Pharmaceutical Suppliers to the Russian Federation.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 209

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 94

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 149

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 161

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 191

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 151

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Scatec Completes Initial Phase of Solar Power Plant Sale

Updated Category News Views 114

Scatec ASA, a heavyweight in the renewable energy arena, concluded the first phase of selling parts of its holdings in the Kalkbult, Linde, and Dreunberg solar power plants back in 2024. This deal was inked with Greenstreet 1 Proprietary Limited—a subsidiary under the STANLIB Infrastructure Fund II umbrella. Transaction Breakdown: Financials and Implications The...

Continue Reading
Taiwan Semiconductor Excels with Strong AI Demand and Profits

Updated Category News Views 227

Taiwan Semiconductor's Remarkable Performance Taiwan Semiconductor Manufacturing Co (NYSE: TSM) has recently reported outstanding financial results for the third quarter, which surpassed expectations and reflected the growing global demand for advanced microchip technologies. Investors celebrated as TSM stock saw gains following these impressive numbers, showing...

Continue Reading
China Eases Mortgage Burdens as Economy Faces Challenges

Updated Category News Views 246

The People's Bank of China (PBOC) dropped a bombshell back in mid-2024, mandating commercial banks to slash interest rates on all existing housing loans. This move was their bid to ease the financial burden on households grappling with an economy that just wouldn’t budge. You see, this wasn’t just some casual tweak; it was a strategic lifeline thrown into the...

Continue Reading
Dimethylolpropionic Acid Market Forecast: Growth Driven by Eco-Friendly Solutions

Updated Category News Views 88

Overview of the Dimethylolpropionic Acid Market The global market for dimethylolpropionic acid (DMPA) is set for substantial growth, with projections indicating an increase of USD 230.2 million from 2024 to 2028, as highlighted in recent analyses. This growth translates to a compound annual growth rate (CAGR) of 7.05%. A key factor driving this expansion is the tightening...

Continue Reading
Bowen Acquisition Corp Faces NASDAQ Delisting Risk Amid Non-Compliance

Updated Category News Views 257

Bowen Acquisition Corp's Delisting Notification from NASDAQ Bowen Acquisition Corp (NASDAQ: BOWN) has recently faced the daunting challenge of a potential delisting from the Nasdaq Global Market. The announcement came as a response to a delisting determination letter received on a notable date which has since raised concerns among investors and stakeholders alike....

Continue Reading